
Opinion|Videos|March 13, 2025
TAR-200 Clinical Development Program in NMIBC
Experts briefly mention other ongoing phase 3 studies investigating TAR-200 for the treatment of non–muscle-invasive bladder cancer (NMIBC).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you briefly mention other ongoing phase 3 studies with TAR-200?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












